Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estrone Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | STS | P08842 | 11/20 | 0.80 |
| ▸ | CA1 | P00915 | 3/20 | 0.80 |
| ▸ | CA2 | P00918 | 3/20 | 0.80 |
| ▸ | CA9 | Q16790 | 3/20 | 0.80 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.80 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.80 |
| ▸ | CA4 | P22748 | 1/20 | 0.80 |
| ▸ | CA6 | P23280 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estrone Sulfuric Acid SCHEMBL939946 | 1.00 | KDM4E (1.00) | KDM4ESTSCA1CA2CA9 | |
| Estrone Sulfuric Acid SCHEMBL28077672 | 1.00 | KDM4E (1.00) | KDM4ESTSCA1CA2CA9 | |
| Estrone Sulfuric Acid SCHEMBL29950318 | 0.98 | KDM4E (0.96) | KDM4ESTSCA1CA2CA9 | |
| Estrone Sulfuric Acid SCHEMBL4812138 | 0.98 | KDM4E (0.96) | KDM4ESTSCA1CA2CA9 | |
| Estrone Sulfuric Acid SCHEMBL2296097 | 0.98 | KDM4E (0.96) | KDM4ESTSCA1CA2CA9 | |
| Estrone Sulfuric Acid SCHEMBL4616 | 0.98 | KDM4E (0.96) | KDM4ESTSCA1CA2CA9 | |
| SCHEMBL21067318 | 0.91 | STS (0.84) | KDM4ESTSCA1CA2CA9 | |
| SCHEMBL8034430 | 0.90 | STS (0.82) | KDM4ESTSCA1CA2CA9 | |
| SCHEMBL17531381 | 0.90 | STS (0.82) | KDM4ESTSCA1CA2CA9 | |
| Emate SCHEMBL10062721 | 0.89 | STS (1.00) | KDM4ESTSCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285565-A1 | POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS | W. L. GORE & ASSOCIATES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11642412-B2 | Polytetrafluoroethylene co-polymer emulsions | W. L. GORE & ASSOCIATES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3819293-B1 | ANGIOTENSIN II RECEPTOR 2 ANTAGONIST SALT FORM AND CRYSTALLINE FORM, AND PREPARATION METHOD THEREFOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-20220401626-A1 | LIQUID COMPOSITION AND POROUS HARDENED MATERIAL COMPRISING TETRAFLUOROETHYLENE AND VINYL MOIETY CO-POLYMERS | W. L. GORE & ASSOCIATES, INC. | 2022-12-22 | — | — | US | disclosed |
| CN-114728096-A | Liquid composition and porous hardened material containing copolymer having tetrafluoroethylene and vinyl moiety | W.L.戈尔及同仁股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210206724-A1 | ANGIOTENSIN II RECEPTOR 2 ANTAGONIST SALT FORM AND CRYSTALLINE FORM, AND PREPARATION METHOD THEREFOR | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-11021445-B2 | Carboxylic acid derivative as AT2R receptor antagonist | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-06-01 | — | — | US | disclosed |
| WO-2021097210-A1 | LIQUID COMPOSITION AND POROUS HARDENED MATERIAL COMPRISING TETRAFLUOROETHYLENE AND VINYL MOIETY CO-POLYMERS | W. L. GORE & ASSOCIATES, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-3819293-A1 | ANGIOTENSIN II RECEPTOR 2 ANTAGONIST SALT FORM AND CRYSTALLINE FORM, AND PREPARATION METHOD THEREFOR | Shandong Danhong Pharmaceutical Co., Ltd. (CN) | 2021-05-12 | — | — | EP | disclosed |
| EP-3620454-B1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-05-05 | — | — | EP | disclosed |
| US-20190000979-A1 | POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS | W. L. GORE & ASSOCIATES, INC. | 2019-01-03 | — | — | US | disclosed |
| US-10092653-B2 | Polytetrafluoroethylene co-polymer emulsions | W. L. GORE & ASSOCIATES, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9731017-B2 | Polytetrafluoroethylene co-polymer emulsions | W. L. GORE & ASSOCIATES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-2895210-A2 | POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS | W. L. Gore & Associates, Inc. (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014043556-A2 | POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS | W.L. GORE & ASSOCIATES, INC. (US) | 2014-03-20 | — | — | WO | disclosed |
| US-20140072518-A1 | POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS | W. L. GORE & ASSOCIATES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072514-A1 | POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS | W. L. GORE & ASSOCIATES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-5610180-A | TOCOPHEROL AND CHOLESTEROL DERIVATIVES, CYTOPROTECTIVE AGENTS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-03-11 | — | — | US | disclosed |
| US-5336485-A | Administering cholestane phthalates, succinates or sulfates before administering tacrine | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1994-08-09 | — | — | US | disclosed |
| US-5198432-A | Cytoprotective agents | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021445-B2 | Carboxylic acid derivative as AT2R receptor antagonist | AGTR2, AGTR1, HCAR2 | ESR1 1219/4885KDM4E 4199/4885STS 3152/4885 |
| US-20210206724-A1 | ANGIOTENSIN II RECEPTOR 2 ANTAGONIST SALT FORM AND CRYSTALLINE FORM, AND PREPARATION METHOD THEREFOR | AGTR2, AGTR1, AVPR2 | ESR1 3639/4885KDM4E 4813/4885STS 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.